Opexa Therapeutics (OPXA) Reaches Enrollment Target In Phase IIb Trial Of Personalized Immunotherapy For Secondary Progressive Multiple Sclerosis
5/13/2014 8:10:04 AM
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today reported it has reached the targeted enrollment in its Phase IIb clinical trial in Secondary Progressive Multiple Sclerosis. As of today, 180 patients with Secondary Progressive MS have been randomized in the Phase IIb “Abili-T” clinical study of Tcelna. The Company will also allow patients who are currently in the screening process at the time of full enrollment and who meet the trial’s entry criteria to also be enrolled in the trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by